Low-Dose Parenteral Soybean Oil for the Prevention of Parenteral Nutrition–Associated Liver Disease in Neonates With Gastrointestinal Disorders
| Autor: | Laura Cerny, Thomas Havranek, Martiniano Flores, Stephen B. Shew, Kara L. Calkins, Lorraine I. Kelley-Quon, Tristan Grogan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 030109 nutrition & dietetics Nutrition and Dietetics food.ingredient business.industry Low dose Medicine (miscellaneous) Direct bilirubin medicine.disease Gastroenterology Soybean oil Surgery Sepsis 03 medical and health sciences Liver disease 0302 clinical medicine Parenteral nutrition food Cholestasis Baseline characteristics Internal medicine Medicine 030211 gastroenterology & hepatology business |
| Zdroj: | Journal of Parenteral and Enteral Nutrition. 41:404-411 |
| ISSN: | 1941-2444 0148-6071 |
| DOI: | 10.1177/0148607115588334 |
| Popis: | Background: Neonates with gastrointestinal disorders (GDs) are at high risk for parenteral nutrition–associated liver disease (PNALD). Soybean-based intravenous lipid emulsions (S-ILE) have been associated with PNALD. This study’s objective was to determine if a lower dose compared with a higher dose of S-ILE prevents cholestasis without compromising growth. Materials and Methods: This multicenter randomized controlled pilot study enrolled patients with GDs who were ≤5 days of age to a low dose (~1 g/kg/d) (LOW) or control dose of S-ILE (~3 g/kg/d) (CON). The primary outcome was cholestasis (direct bilirubin [DB] >2 mg/dL) after the first 7 days of age. Secondary outcomes included growth, PN duration, and late-onset sepsis. Results: Baseline characteristics were similar between the LOW (n = 20) and CON groups (n = 16). When the LOW group was compared with the CON group, there was no difference in cholestasis (30% vs 38%, P = .7) or secondary outcomes. However, mean ± SE DB rate of change over the first 8 ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text